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Interleukin-15 (IL-15) is a cytokine that has been shown to expand CD8 T cell and natural
killer (NK) cell populations, and therefore has potential for potentiating adoptive immune
cell therapy for cancer. Previously, IL-15 has been shown to induce proliferation of CD8
memory T cells through activation of telomerase. Here, we investigated whether
telomerase is also activated during the IL-15 mediated proliferation of NK and NKT-like
(CD56+CD3+) cells. We also examined the extent that each of the three signaling
pathways known to be stimulated by IL-2/IL-15 (JAK-STAT, PI3K-AKT Ras-RAF/
MAPK) were activated and involved in the telomerase expression in the three cell types
NK, NKT, or CD8 T cells. To assess cell proliferation and doubling, peripheral blood
mononuclear cells (PBMCs) or isolated NK, NKT-like or CD8 T cells were incubated with
varying concentrations of IL-15 or IL-2 for 7 days. CD8 T, NK, and NKT cell expansion was
determined by fluorophore-conjugated antibody staining and flow cytometry. Cell
doubling was investigated using carboxyfluorescein-succinimidyl-ester (CFSE).
Telomerase expression was investigated by staining cells with anti-telomerase reverse
transcriptase (anti-TERT). Telomerase activity in CD56+ and CD8 T cells was also
measured via Telomerase Repeat Amplification Protocol (TRAP). Analysis of cellular
expansion, proliferation and TERT expression concluded that IL-15 increased cellular
growth of NK, NKT, and CD8 T cells more effectively than IL-2 using low or high doses. IL-
15, increased TERT expression in NK and NKT cells by up to 2.5 fold, the same increase
seen in CD8 T cells. IL-2 had effects on TERT expression only at high doses (100–1000
ng/ml). Proteome profiling identified that IL-15 activated selected signaling proteins in the
three pathways (JAK-STAT, PI3K-AKT, Ras-MAPK) known to mediate IL-2/IL-15
signaling, more strongly than IL-2. Evaluation by signaling pathway inhibitors revealed
that JAK/STAT and PI3K/AKT pathways are important in IL-15’s ability to upregulate
TERT expression in NK and NKT cells, whereas all three pathways were involved in CD8 Torg January 2021 | Volume 11 | Article 5946201
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Frontiers in Immunology | www.frontiersin.cell TERT expression. In conclusion, this study shows that IL-15 potently stimulates TERT
upregulation in NK and NKT cells in addition to CD8 T cells and is therefore a valuable tool
for adoptive cell therapies.Keywords: interleukin-15, interleukin-2, telomerase, cell-signaling, adoptive cell therapyINTRODUCTION
Advances in the understanding of anti-cancer immunity has
resulted in the successful use of immunotherapies against a
number of cancers with checkpoint inhibitor antibodies such as
the anti-CTLA-4 antibody Ipilumimab,(Yervoy™) and anti-PD1
antibodies Pembrolizumab, (Ketruda™) and Nivolumab,
(Opdivo™) becoming FDA approved for a number of cancers
(1). Alongside the development of these agents, adoptively
transferred immune cell therapies, which have been trialed for
over 20 years with disparate results, are now becoming more
successful with the use of the chimeric antigen receptor (CAR) T
cells, dendritic cells and allogeneic or syngeneic NK cells (2, 3).
However, not enough is known about the lifespan of these cells, how
long they remain active, and whether they can withstand the tumor
microenvironment without being rendered anergic or regulatory.
IL-2 and IL-15 are cytokines that have been used to expand
these immune cells before adoptive transfer, or for use as
adjuvants to these cells once administered. Both cytokines can
stimulate the proliferation of NK cells. IL-2 has been FDA
approved for single agent administration to patients with renal
cell carcinoma and melanoma (4), while, IL-15 has been
administered in a number of first in man studies to patients
with metastatic cancer (5, 6). However, IL-15 is believed to be
favorable for use in patients compared with IL-2 due to its
relative lack of toxicity, such as the lack of major resulting
vascular leak syndrome (7). Additionally, unlike IL-2, IL-15
does not significantly affect the numbers and function of
regulatory T (Treg) cells, which are stimulated by various
cancers to induce suppression of CD8+ T cells and NK cells (8,
9). IL-15 can also increase the numbers and survival of both
naïve and memory CD8 T cells (10). IL-15 also stimulates
proliferation of NK and NKT cells (11–14), and IL-15
knockout mice have been shown to have decreased total
numbers of these cell types (15). Furthermore, IL-15 was
recently selected from a large panel of cytokines as the only
agent that can significantly expand NK and CD8 T effector
populations in the presence of prostate tumor cells (16).
The IL-15 receptor is composed of a b subunit (IL-2R/15Rb/
CD122) and a g subunit (CD132) that is shared with the IL-2
receptor, and a distinct a subunit (IL-15Ra) giving the receptor
specificity to the IL-15 cytokine (14). Three separate pathways
are known to be activated by IL-15 ligation to its receptors: the
JAK-STAT, the PI3K-AKT, and the Ras-MAPK pathways:
Strong proliferative signals are induced via JAK/STAT and
Ras/MAPK signaling pathways, and cell death is prevented by
increasing anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, and
decreasing pro-apoptotic proteins such as Bim through
activation of the PI3K pathway (17).org 2IL-15 is thought to act via a number of mechanisms to
increase immune effector cell longevity. One such mechanism
in CD8 T cells is through stimulation of telomerase. Telomerase
is an enzyme that extends telomere length. Telomeres are DNA
repeats found at the end of chromosomes that play a protective
role in preventing genomic instability by blocking end-to-end
fusion of chromosomes during cell division. These telomere
repeats shorten after each cell replication cycle and eventually
deplete leaving the chromosome ends to become exposed.
Subsequently, genome instability occurs resulting in apoptosis
(18). Telomerase activity has been shown to be important in the
regulation of telomere length and consequently, replicative life
span of lymphocytes in a controlled manner: Over-activation of
the enzyme is a mechanism by which cancer cells can proliferate
indefinitely. Telomerase consists of telomerase RNA (TERC) and
telomerase reverse transcriptase (TERT) (19). Whereas TERC
provides a template for telomere synthesis and is widely
expressed in mammalian cells, TERT expression is restricted to
cells with telomerase activity, including lymphocytes, and
undergoes regulation via transcription, mRNA splicing and
translation. Therefore TERT is the rate-limiting component of
the reaction (20).
IL-15 has been shown to increase CD8+ memory T cell
longevity by inducing telomerase activity through JAK3 and
PI3K signaling pathways (21). The products of these pathways,
NFkB, STAT3, c-Myc, and others have been identified as
transcription activators that target the TERT promoter to
restore and maintain telomere length for continuous cell
proliferation and longevity (22).
In this study we examined whether IL-2 or IL-15 upregulate
telomerase expression in NK and NKT-like cells in addition to
CD8 T cells. We chose to study NKT-like cells, with the
phenotype CD56+CD3+ and not other types of NKT cells
(iNKT cells and type II NKT cells) due to their ability to be
stimulated without antigenic restriction. Classical invariant NKT
( iNKT) ce l l s a re CD1d-res t r i c t ed Va24/Vb11+a -
galactosylceramide (a-GalCer)-reactive T cells and Type II
NKT cells are thought to have regulatory functions rather than
an anti-tumor immune functionality whereas NKT-like cells are
CD1d-independent and express diverse T-cell receptors (TCRs)
(23). We also chose NKT-like cells due to reports of their strong
toxicity against tumors (24), a role in treating hematopoietic
malignancy (25) and the association of the progression of some
cancers with a lack of this cell population (26).
There are, however, reports that CD8+NKT-like cells can
inhibit the T-cell response by killing antigen bearing DCs (27).
This also may explain the association of acute T−cell−mediated
renal allograft rejection (ACR) with reduced infiltrating NKT-
like cells. However, it has also been reported that they will killJanuary 2021 | Volume 11 | Article 594620
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function may be therefore be beneficial in cancer patients
with allografts.
Our investigation was additionally based on using bulk CD8
T cells, consisting of both naïve and memory cells, isolated from
peripheral blood mononuclear cells, and not CD8 memory T
cells due to the use of both memory and naïve T cells in adoptive
therapies and the finding that naïve T cells may be as useful as
memory T cells in these therapies because of their lower level of
“exhaustion”, and greater ability to sustain replicative potential
correlative to telomere length (28).
We investigated which of the three known pathways (JAK-
STAT, PI3K-AKT Ras-MAPK) were activated in the each of the
three cell types by IL-15 or IL-2 and the role of these pathways in
the telomerase activity of these cells. We also compared the
ability of IL-2 and IL-15 to expand and increase the proliferation
and doubling capacity of NK, NKT, and CD8 T cells.
The study aimed to identify the optimal doses of IL-2 and IL-
15 for use in expanding NK and NKT-Like, and CD8– T cells for
adoptive transfer therapies and to define which pathways were
most important for the effective proliferation of these cells.MATERIALS AND METHODS
Cytokines Used
Recombinant human IL-15 and IL-2 were obtained from
PeproTech EC Ltd. (London, UK) and reconstituted from
lyophilized protein to give a stock concentration of 10 mg/ml
in sterile PBS.
Isolation of Peripheral Blood
Mononuclear Cells
Blood was collected from blood cones obtained from
anonymized healthy donors (Blood Transfusion Service, NHS
Blood and Transplantation), and PBMCs were isolated as
previously described (29) and then prepared at 3 x 106 cells/ml
in culture medium containing Roswell Park Memorial Institute
medium (RPMI) (Gibco, UK), fetal bovine serum (FBS) (Life
Technologies, Paisley, UK), L-glutamine (Gibco, UK), mycoKill
(PAA, UK), pen-strep (Gibco, UK) and gentamycin (Sigma, UK)
(Complete medium). Cell solutions were transferred to 175 cm2
flasks and left to incubate at 37°C in a humidified 5% CO2
atmosphere for 3 h. The non-adherent PBMCs were then
centrifuged at room temperature for 5 min, the supernatant
was discarded and the pellets were re-suspended in complete
medium for the proliferation assays.
Preparation of Purified NK, NKT-Like, and
CD8 T Cells
PBMCs prepared from the anonymized blood cone donors were
used to isolate purified cell populations. CD56+ cells, NK cells,
NKT-like cells, and CD8 T cells were isolated using kits 130-050-
401, 130-092-657, 130-093-064, and 130-096-495 respectively
from Miltenyi Biotech (Woking, UK) Cells were isolated
according to the manufacturer’s instructions before treatment
with our agents. Cells were checked for purity by staining withFrontiers in Immunology | www.frontiersin.org 3anti-CD56, anti-CD3, and CD8 fluorophore conjugated
antibodies (clones MEM-188), (clone HIT1A) BioLegend UK,
and clone BW135/80) (Miltenyi Biotech, Woking, UK)
respectively followed by flow cytometric analysis using a BD
FACSCalibur (BD Biosciences, Poole, Dorset, UK). Cells were
prepared at a concentration of 8 x 105 cells/ml for proliferation
studies or cell signaling analysis.
Lymphocyte Proliferation Assays
One ml of isolated non-adherent PBMCs or purified NK, NKT-
Like or CD8 T cells (8 x 105 cells) prepared in complete medium
was placed in multiple wells of 24-well plates. 10 µl of differing
concentrations of IL-15 or IL-2 diluted in phosphate buffered
saline (PBS) (Severn Biotech Ltd, UK) were added to the wells or
PBS was added as a negative control. Plates were then left to
incubate at 37°C in a humidified 5% CO2 atmosphere for 7 days
with additional doses of cytokines added at day 4.
Surface Antibody Staining
Cells were removed from wells after the incubation period and
transferred to Facs tubes for staining with antibodies for FACS
analysis using standard protocols to detect surface markers
(https://www.biolegend.com/protocols/cell-surface-flow-
cytometry-staining-protocol/4283/). The antibodies used were
fluorophore conjugated anti-CD3, anti-CD56, anti-CD4 (clones
MEM-188, HIT1A, clone A161A1, respectively, BioLegend, UK),
and anti-CD8 antibodies(clone BW135/80, Miltenyi, UK).
Antibody staining was analyzed using a BD Calibur Flow
cytometer (BD Biosciences Poole, Dorset, UK).
Determination of Cell Expansion
Percentage expressions of NK (CD56+/CD3-) cells, NKT-Like
(CD56+/CD3+) cells, CD4 and CD8+ T cells in the lymphocyte
populations were analyzed through flow cytometry using
CellQuest (BD Biosciences, USA) or FlowJo software (FlowJo,
USA). Percentage gated values at quadrants corresponding to the
different cell types were taken to compare cell expansion at the
different IL-15 concentrations. The lymphocytes were gated on live
cells within the lymphocyte population. Viability of the lymphocyte
populations in the presence of the cytokines was measured using a
live/dead stain (Live/Dead Fixable Near-IR Dead Cell staining
(ThermoFisher Scientific, Paisley, UK) with analysis using the
FACs canto flow cytometer BD Biosciences, Dorset UK).
Determination of Cell Replicative Capacity
via CFSE Staining
The Carboxyfluorescein succinimidyl ester (CFSE) Cell
Proliferation Kit (PromoKine, Germany) was used to form a
stock concentration of 5mM CFSE, which was diluted to 1mM
using PBS. Following incubation of isolated PBMCs at 37°C for
3 h, the non-adherent cells were washed by centrifugation for
5 min at room temperature and the pellets were re-suspended in
pre-warmed (37°C) CFSE solution in PBS. The cells were
incubated for 15 min at 37°C to label the cells. The labeled cells
were then centrifuged for 5 min at room temperature and the
pellets were re-suspended in culture medium at a concentration of
8 x 105 cells/ml ready for incubation with cytokines.January 2021 | Volume 11 | Article 594620
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following incubation with cytokines. Histograms of cell count
against CFSE expression were set for each cell type at each
concentration of cytokines. The geometric mean fluorescence
was taken from each histogram to quantify the expression of
CFSE and the number of cell divisions per population was
calculated from the decrease of the Geometric mean where a
50% decrease was taken as 1 cycle of cell division.
Determination of Telomerase Expression
via TERT Staining
Following incubation with cytokines and subsequent surface
antibody staining an intracellular staining protocol was carried
out using a Cytofix/Cytoperm kit (BD Sciences USA) according
to manufacturer’s instructions whereby APC-conjugated anti-
TERT antibody (Bioss, USA) was incubated with the cells.
Telomerase expression, as measured by TERT expression was
measured for each cell type by analyzing the geometric mean
values from histogram plots of cell count against TERT
expression for each cell population at each concentration of IL-
15 or IL-2. The LNCaP cell line purchased from ECACC (Public
Health of England, Salisbury, UK), was used as a positive control
for the expression of HTERT in selected experiments. Cells were
cultured in RPMI 1640 medium (Sigma Aldrich, Poole, UK)
supplemented with 2 mM glutamine, 1% antibiotic antimycotic
solution and 10% fetal bovine serum (ThermoFisher Scientific,
Paisley, UK). The cells were stained with anti-HTERT as above
without previous treatment or surface antibody staining and
were washed 3 times with PBS before antibody staining.
Telomere Repeat Amplification Protocol
Purified CD56+ cells or CD8 T cells isolated by Miltenyi
microbeads were prepared at 8 x 105 cells/ml in 24 well plates
with different concentrations of IL-15 for 7 days. The telomerase
activity of the cells was assessed by a TRAP assay using the
Telomerase PCR ELISA kit (Roche, Germany) according to the
manufacturer’s protocol.
Analyses of Cytokine Induced
Phosphorylation of Proteins From the
JAK/STAT/MEK and PI3K Pathways
Purified effector cells were prepared in RPMI complete medium
at a concentration of 8 x 105 cells per ml and incubated for 24 h
in 6-well plates with either 0.1 ng/ml IL-2, 1000 ng/ml IL-2,
2.5ng/ml IL-15 (for optimal NK cell proliferation) or 50 ng/ml
IL-15 (for optimal NKT-like or T cell proliferation). Cells were
then lysed in Lysis buffer containing protease inhibitors and
phenylmethanesulfonyl fluoride (PMSF) and lysates were
prepared according to the manufacturers protocol for the
Human Phospho-Kinase Array Kit (R&D Systems, Abingdon,
Oxford, UK). Protein concentration of samples was quantified
using a Coomassie (Bradford) Protein Assay Kit (ThermoFisher
Scientific, Dartford, UK). Protein samples were stored at -80°C
until protein analysis was continued.
Using the manufacturers protocol for the Human Phospho-
Kinase Array (R&D Systems, Abingdon, Oxford, UK), cell lysateFrontiers in Immunology | www.frontiersin.org 4samples from each treatment were applied to a Part A membrane
and a Part B membrane, containing complementary antibodies
corresponding to different signaling proteins. The prepared
membranes were analyzed using an ImageQuant LAS 4000
mini machine and the software ImageQuant 4000 (Ge
Healthcare, Amersham UK). Image Studio Lite software
analyzed the quantity of intensity of each membrane dot
produced in these images that correlated to a specific protein.
Each protein from each cell type was represented by two dots
with their average being used to develop bar charts with error
bars and a dot diagram to make a comparison between the low
dose IL-2 control, IL-2, and IL-15. This procedure was repeated
again with an alternative donor for all cell types to validate
the results.
To confirm the results of the array, western blots were carried
out with the proteins showing significant changes in
phosphorylation with the different cytokines. Lysates were
mixed with 4ul of 10x reducing agent (NuPAGE Sample
Reducing Agent) and 10ul of 4x SDS-PAGE sample loading
buffer (LDS 4x Sample buffer) (ThermoFisher scientific Dartford,
UK) and subsequently heated at 95°C for 5 min and spun briefly.
Samples were resolved on 4%–12% Bis-Tris gels and transferred
to the iBlot nitrocellulose membrane using the iBlot Dry Blotting
System (Invitrogen, UK). Western blots were performed using
p38a (T180/Y182), CREB S133, ERK1/2 (T202/Y204, T185/
Y187), AMPKa1 (T183), STAT5a (Y694), STAT5a/b (Y694/
Y699), P53 (S392), AKT1/2/3 (S473), AKT1/2/3 (T308),
Hsp60, mTOR (Ser2448), and GAPDH as the primary
antibodies (Cell Signal, London, UK) and a HRP-linked anti-
rabbit IgG antibody as the secondary antibody. Detection of the
proteins were done using ECL chemiluminescence reagent (GE
Healthcare, Amersham, UK). Where required, membranes were
stripped using the western blot stripping buffer for 15 min and
reprobed with another antibody. Blots were photographed and
saved as TIF files from the ImageQuant LAS 4000 mini (GE
healthcare, UK).
Effects of Signaling Pathway Inhibitors on
TERT Expression in the NK, NKT-Like, and
CD8 T Cells
Non-adherent PBMCs were aliquoted at 8 x 105 cells/ml in 24-
well plates together with the optimal concentrations of cytokines
found to increase TERT expression for each cell type (NK, NKT-
like or CD8 T cells), or controls (either PBS alone or 0.1 ng/ml
IL-2) for 7 days either alone or in the presence of inhibitors of
each of the three signaling pathways known to be impacted by
IL-2/IL-15. The CP690550 JAK1/3 inhibitor (BD Biosciences,
Poole, Dorset, UK), was used at 10 µM for JAK1 inhibition and
0.1 µM for JAK3 inhibition (30). The LY-294002 hydrochloride
PI3K/AKT inhibitor (Sigma, UK) (31) was used at 4 µM and the
MEK/ERK inhibitor U0126 (32) (Promega, Southampton, UK)
at 10 µM.
Statistical Analyses
Data were plotted either as raw values of percentage expression
or normalized to the untreated control of each experimentalJanuary 2021 | Volume 11 | Article 594620
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for more accurate comparison between experiments. Raw or
normalized mean values along with their standard errors were
calculated for each experiment. Ordinary one-way ANOVA was
carried out using the program GraphPad Prism 8 (GraphPad
Software, La Jolla, CA) for all data to determine a 95% level of
statistical significance. Post hoc Newman Keuls multiple
comparison tests were carried out where appropriate for
comparison of data from various concentrations of cytokines
against control data without cytokines. The results are all
expressed as differences seen from lymphocytes taken from the
same donor and treated with the different cytokines and doses,
with analysis as repeated measures anovas. In the figure legends
where n numbers are mentioned, these describe experiments
from separate donors. Therefore, if n = 6, six separate
experiments were performed from six independent donors.RESULTS
IL-15 Is Superior to IL-2 in Expanding NK,
NKT-Like, and CD8 T Cells
IL-2 and IL-15 induced expansion of NK, NKT-like and CD8 T
cells in populations of non-adherent PBMCs was investigated by
determining the percentage expression of these cells in a
population of gated lymphocytes after 7 days incubation with
the cytokines. Figure 1A displays the flow cytometric gating to
measure the NK, NKT-like and CD8 T cells within the non-
adherent PBMC population. Figure 1B shows that IL-15
upregulated expression significantly from a concentration of
0.1 ng/ml in NK cells, 1 ng/ml in NKT-like cells and 25 ng/ml
in CD8 T cells. A ten-fold maximal increase in expression
occurred at 2.5 ng/ml in NK cells, and at 25–100 ng/ml in
NKT-like cells. CD8 T cells were significantly increased by 1.5
fold from 25 ng/ml to 100 ng/ml.
IL-2 incubation resulted in a more modest increase in
expansion with a 5-fold increase occurring from 100–1000 ng/
ml in NK and NKT-like cells whereas CD8 T cells were expanded
by 1.3 fold at 1000 ng/ml. CD4 T cells were not expanded at any
dose either by IL-15 or IL-2. Purified NK, NKT, and CD8 T cells
also show increased expansion when treated with IL-15 or IL-2
(Figure 1C). NK cells, NKT-like cells and CD8 T cells were
isolated before we treated then with our agents as we wanted to
examine the effects of the cytokines on the growth of the
individual cell types. We also examined cell expansion at days
2, 7, and 14 to compare the growth rate obtained by the two
cytokines (Figure 1D). These demonstrate that for NK and
NKT-like cells, IL-15 is superior to IL-2 at increasing cell
expansion and whereas IL-2 induced growth plateaus at day 7,
NK, and NKT cell growth increases beyond 7 days although
growth plateaus for IL-15 as well at 14 days.
The gated lymphocytes analyzed represent the live
lymphocyte population as confirmed with comparing gating
obtained from live/dead reagents with this lymphocyte gate.
The live/dead staining also confirms that lymphocytes treatedFrontiers in Immunology | www.frontiersin.org 5with PBS or 25 ng/ml IL-15 concentrations have over 97% viable
lymphocytes (Figure 1 Supplementary section). The purity of
the NK, NKT, and CD8 T cells is shown in Figure 2
Supplementary section.
IL-15 Is Superior to IL-2 in Increasing Cell
Doubling Capacity in NK, NKT-Like, and
CD8 T Cells
The effect of IL-15 and IL-2 on the cell doubling capacity was
investigated using CFSE cell proliferation assay. Figure 2 shows
the effects of IL-2 and IL-15 on NK, NKT-like and CD8 T cell
proliferation as expressed by the geometric mean fluorescence of
CFSE after 7 days. Panel A displays the flow cytometric gating,
panel B displays the normalized geometric mean fluorescence
obtained with different concentrations of IL-2 and IL-15, and
panel C shows the number of cell divisions observed above that
of the control cell population (with no cytokines). The numbers
of cell divisions were calculated from the geometric mean
fluorescence intensity of the cells by using 1 cell division as
equivalent to a 50% decrease in the geometric mean of CFSE.
These results showed that as the concentration of IL-15 increased
there was a significant decrease in this geometric mean
fluorescence, with a maximal decrease at 25ng/ml IL-15 for
NK cells (p=0.004) and at 50ng/ml IL-15 for NKT-like and
CD8+ T cells (p=0.0001 and n=6; p=0.0026, respectively). These
results correspond to a maximal four extra divisions in NK cells
and seven divisions in NKT-like cells. In CD8 T cells there is a
maximal extra three divisions with IL-15. For IL-2, significant
decreases in geometric mean and the subsequent increased cell-
division (maximal 2.49, 2.8, and 2.2 in NK, NKT-like and CD8 T
cells, respectively) were only observed at 500–1000 ng/ml in each
of the three cell types (n=6, p<0.001 by one way anova and post-
hoc Newman Keuls).
IL-15 Upregulates Telomerase TERT in
NK, NKT-Like, and CD8 T Cells at Lower
Doses Than IL-2
Telomerase expression was measured by the detection of TERT
in the effector cells. Figure 3A shows flow cytometric dot plots
and histograms showing the expression of TERT on the 3 effector
cell types, NK, NKT-like, and CD8 T cells. All three cell types
express TERT without cytokine activation. An LNCaP cell line
which has been shown previously to highly express HTERT (33)
has been stained with HTERT as a positive control and is shown
in the histogram for comparison of its HTERT expression to NK
cells. The geometric mean of expression, signifying the intensity
of expression per cell, is increased significantly in all three cell
types by IL-15 compared with without any cytokines after 7 days
(Figure 3B): In NK cells, expression is increased from 2 fold at
2.5 ng/ml up to 2.8 fold at 50 ng/ml (p<0.01). In NKT-like cells,
expression is increased from a mean of 1.7 fold at 2.5 ng/ml up to
2.2 fold at 100 ng/ml (p<0.01). In CD8 T cells, TERT is increased
from 1.6 fold at 2.5 ng/ml to 2.6 fold at 100 ng/ml (p<0.01). IL-2
treatment resulted in a more modest increase in TERT
expression: In NK cells, expression increased significantly by 2January 2021 | Volume 11 | Article 594620
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seen up to 100–1000 ng/ml by up to 2.5 fold (p<0.01). In NKT-
like cells, IL-2 treatment produced similar increases to IL-15 (up
to a 2.5 fold increase from untreated cells) but again, these were
at higher doses (100–1000 ng/ml), (p<0.01).
To further confirm the efficacy of IL-15 in increasing activity
of telomerase, we performed a TRAP assay on isolated CD56+
cells and CD8 T cells. Figure 3C shows that telomerase activity,
as measured by the 490 nm absorbance of reactions from the
telomerase PCR ELISA, is increased by IL-15 in both CD56+
cells and CD8 T cells.Frontiers in Immunology | www.frontiersin.org 6IL-15 and IL-2 Induce Differential
Phosphorylation of Proteins From the
Three Signaling Pathways JAK/STAT, P13/
AKT, and RAS/MAPK
Cell lysates obtained from NK, NKT-like and CD8 T cells treated
with IL-15 or IL-2 were used in a Human Phosphokinase array
protein array to assess phosphorylation of a range of proteins in
the three signaling pathways impacted by IL-2 and IL-15 (JAK/
STAT, P13/AKT, and RAS/MAPK). From the array analysis, two
membrane images were developed displaying two sets of dots




FIGURE 1 | Expansion of immune effector cell populations treated for 7 days with IL-15 at concentrations from 0.01 ng/ml to 100 ng/ml or IL-2 from 0.1 to 1000
ng/ml with PBS as a control. (A) Gating strategy for NK cells, NKT-like cells and CD8 T cells in the PBMC population showing the significant increase in CD56+CD3-
cells (NK cells), CD56+CD3+ (NKT cells) and (CD3+CD8+) (CD8 T) cells in non-adherent PBMCs treated with IL-15. (B) displays quantitated expression of NK, NKT,
CD8 T cells and CD4 T cells in lymphocytes treated with different doses of IL-15 or IL-2. (C) shows increased total percentage of purified NK, NKT, and CD8 T cells
upon incubation with IL-2 or IL-15. (D) shows the expansion of the three cell types over a time period with time points at days 2, 7, and 14 using IL-15 at 2.5 ng/ml
for NK cells and 25 ng/ml with a more pronounced expansion with IL-15 compared to IL-2 in NK and NKT-like cells. Results are expressed as % of the expansion of
the untreated lymphocytes and represent means ± SEM from six separate experiments (*p < 0.05, **p < 0.01 and ***p < 0.001 by one-way ANOVA and Newman
Keuls post-hoc analysis).January 2021 | Volume 11 | Article 594620
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase ExpressionFrom Figures 4A, B, NK cells show the least changes in
phosphorylation of proteins from the array: IL-15 treatment
increases Creb, Stat5a/b, Tor, AMPK a1, AKT (T308), and
Hsp60 protein phosphorylation intensities above the low IL-2
control samples, whereas 1000 ng/ml IL-2 increases Creb, AMPK
a1, Stat5a/b, and Stat2 phosphorylation. In NKT cells, IL-15 also
increases Creb. Stat5a/b, Tor, AKT (T308) AMPKa1, and Hsp60
whereas IL-2 increases Stat2, AMPKa1, Stat5a, Stat5a/b, Stat5b,
Stat6, and Creb. CD8 T cells display higher levels of
phosphorylated proteins at the baseline (1ng/ml IL-2) level. IL-
15 upregulates Creb, p38, ERK1/2, AKT (S473), AKT (T308),Frontiers in Immunology | www.frontiersin.org 7AMPKa1, p53 (s392), (s46), WNK1, Hsp60, Stat2, Stat5a, Stat5b,
Stat5a/b, Stat6 in CD8 T cells, whereas IL-2 only upregulates
AMPKa1, Creb, Stat2, Stat5a, Stat5b, Stat5a/b, and Stat6.
When we carried out western blots of selected proteins to
confirm changes in the array (Figure 4C), IL-15 activity was
confirmed for Creb, Stat5a/b, Tor, and Hsp60 in NK cells. In
NKT cells, there was additional activity confirmed for AKT
(T308) and in CD8 T cells, additional activity was seen with
p53, ERK1,2,3 p38a and AMPKa1. For IL-2, only Stat5a/b
activity was confirmed with the western blot, with no increases
seen in Creb or AMPKa1.A
B
C
FIGURE 2 | Effects of IL-15 and IL-2 on cell doubling capacity. Non-adherent PBMCs premixed with CFSE were treated for 7 days with concentrations of IL-15
from 0.1–100 ng/ml and IL-2 from 0.1 to 1000 ng/ml with PBS as a control. (A) displays the dot plots and a representative histogram showing the representative
CFSE staining of a population of CD56+CD3- NK cells in the PBMCs. CFSE staining is measured as the geometric mean of the gated NK cell population and a
decrease in the geometric mean signifies an increase in cell division. (B) shows the effects of IL-15 and IL-2 on NK, NKT-like and CD8 T cell proliferation as
expressed by the normalized geometric mean fluorescence of CFSE after 7 days. (C) shows the number of cell divisions observed above that of the control cell
population (with no cytokines). The numbers of cell divisions were calculated from the geometric mean fluorescence intensity of the cells by using 1 cell division as
equivalent to a 50% decrease in the geometric mean of CFSE. Results represent means ± SEM from six separate experiments (* p < 0.05 by one-way ANOVA and
Newman Keuls post-hoc analysis).January 2021 | Volume 11 | Article 594620
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase ExpressionEffects of Inhibitors of the Three Signaling
Pathways on TERT Expression in the
Three Cell Types
Figure 5 displays bar charts of TERT expression in the three cell
types where cells were treated with the inhibitors from the three
signaling pathways JAK/STAT, P13/AKT and RAS/MAPK. The
results are expressed as normalized geometric mean values of
TERT, normalized cell expansion and normalized cell divisions
obtained from the geometric mean values of the CFSE stainingFrontiers in Immunology | www.frontiersin.org 8obtained from the flow cytometric analysis. Without inhibitors,
TERT expression is increased by IL-2 and IL-15 by 2-2.5 fold in
the three cell types as previously shown in the TERT
experiments. All inhibitors of the three pathways (CP690550,
LY-294002 hydrochloride, and U0126) abrogated IL-2 induced
increases in TERT expression in the three cell types. The
CP690550 inhibitor (used at two different doses to inhibit
JAK1 and JAK3 signaling), also abrogated IL-15 induced
increases in TERT expression in all three cell types. The MEK/A
B
C
FIGURE 3 | Effects of IL-15 and IL-2 on the expression of TERT in NK, NKT, and CD8 T cells in non-adherent PBMCs after 7 days culture. (A) shows dot
plots and histograms displaying TERT as detected by flow cytometric analysis using Alexa-Fluor647 conjugated anti-TERT antibodies. Cells were also stained
with fluorophore conjugated anti-CD8, anti-CD56, and anti-CD3 to distinguish the NK, NKT-like, and CD8 T cell populations. In (B), results are expressed as
the TERT geometric mean values from each experiment normalized to the PBS control. IL-15 induces significant increases in TERT in NK, NKT, and CD8 T
cells starting at concentrations of 2.5 ng/ml. IL-2 also significantly increases TERT expression at concentrations from 100 ng/ml to 1000 ng/ml. Results
represent means ± SEM from six separate experiments (six donors)(* p < 0.05 by one-way ANOVA and Newman Keuls post-hoc analysis). (C) shows
telomerase activity in CD56+ and CD8+ T cells. measured via a TRAP assay after 7 days incubation with IL-15. Four concentrations of IL-15 were used: 0, 2.5,
25 and 100 ng/ml, with six repeats carried out. Results showed that as the concentration of IL-15 increased there was a rise in absorbance, indicating
telomerase activity in the CD56+ and CD8 T cells.January 2021 | Volume 11 | Article 594620
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FIGURE 4 | The effects of IL-15 and IL-2 on the expression of phosphorylation of proteins from the three signaling pathways JAK/STAT, P13/AKT, and RAS/MAPK.
(A) shows membrane dot images developed from probing of the three cell types (NK, NKT, and CD8 T cells) treated with 1ng/ml IL-2 with the two membranes from
a representative donor. The intensity of the dots relates to the detection of phosphorylated protein intensity within a certain sample. (B) displays a heatmap of the
protein array collated from repeated experiments (n=4), with the proteins arranged by their signaling pathways and with colors indicating the degree of upregulation
of phosphorylated proteins as calculated by densitometry carried out on the developed membranes. Yellow represents no change in expression compared to the
low dose IL-2 control. Light green = protein expression increased by 1.1 fold -1.5 fold. Dark green = expression increased by more than 1.5 fold. Cream indicates no
protein expression. (C) displays western blots of proteins selected from the array that showed increased phosphorylation (or upregulation of protein in the case of
Hsp60).Frontiers in Immunology | www.frontiersin.org January 2021 | Volume 11 | Article 5946209
nsion (B), and cell divisions from CFSE data (C) in NK, NKT-like and CD8 T cells.
und to increase TERT expression for each cell type (2.5 ng/ml IL-15 and 1000 ng/ml
, or controls (PBS)]. Cells were incubated for 7 days either with cytokines/control only
(J1) and JAK3 (J3) inhibition dependent on concentration, LY-294002 hydrochloride
xpressions of TERT, normalized cell expansion, and normalized numbers of cell








































FIGURE 5 | Effects of inhibitors of JAK1, JAK3, MEK/ERK, and PI3/AKT on the upregulation of expression of TERT (A), cell expa
Non-adherent PBMCs were aliquoted at 8 x 105 cells/ml in 24-well plates together with the optimal concentrations of cytokines fo
IL-2 for NK cells, 25 ng/ml IL-15 and 1000 ng/ml IL-2 for NKT-like cells and 25 ng/ml IL-15 and 1000 ng/ml IL-2 for CD8 T cells)
or in the presence of inhibitors of each of the three signaling pathways known to be impacted by IL-2/IL-15 [CP690550 for JAK1
(P) for PI3K/AKT inhibition and U0126 (M) for inhibition of MEK/ERK]. Results are expressed as the normalized geometric mean e
divisions and are the means +/- SEM from six separate experiments. The comparisons are between the each of the no inhibitor c
each of the inhibitors. (*p < 0.05, **p < 0.01 by one-way ANOVA and Newman Keuls post-hoc analysis).
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase ExpressionERK inhibitor significantly reversed IL-15 mediated increases in
TERT expression only in CD8 T cells. The P13K/AKT inhibitor
LY-294002 hydrochloride partially inhibited IL-15 increases in
TERT expression in NK cells and abrogated its expression in
NKT cells and CD8 T cells. Therefore all three pathways are
involved in the IL-2 mediated increases in TERT in the three cell
types, whereas IL-15 mediated increases in TERT involve all
three pathways only in CD8 T cells: PI3K and JAK1/3 are
involved in NKT cell TERT upregulation and in NK cells, only
JAK1/3 inhibition fully inhibits increases in TERT expression
with IL-15. Results obtained from the CFSE and expansion
evaluations of the different cell types concur with the patterns
of HTERT inhibition with the three inhibitors therefore showing
that HTERT expression, cell expansion and division are similarly
affected by the inhibition of the three pathways.DISCUSSION
Effector NK cells, CD8 T cells and NKT-like cells have been
shown to effectively kill tumor cells in vivo when adoptively
transferred. Both the systemic levels of effector NK, NKT-like
and CD8 T cells and their infiltration and activity in tumors
correlates with patient survival in a number of cancer types (34–
38). IL-2 and IL-15 have been identified as agents that can
expand these cells in protocols where they are either injected
systemically or used to treat effector cells that are then adoptively
transferred. Identifying the optimal doses and understanding the
mechanisms by which these two agents enhance effector cell
proliferation is critical to their successful use in patients.
Our study shows that IL-15 is clearly superior to IL-2 in its
expansion and cell doubling capacity of NK, NKT-like, and CD8 T
cells. Doses of IL-15 required for expansion and cell doubling are
between 50 and 100 times less than for IL-2 with significant
expansion occurring from 0.5 ng/ml in NK cells, 1 ng/ml in NKT
cells, and 25 ng/ml in CD8 T cells, whereas IL-2 only increases
expansion from 100 ng/ml in NK and NKT cells and at 1000 ng/
ml in CD8 T cells. These higher doses of IL-2 can also result in the
production of Tregs (39). We have previously shown that Tregs
are not upregulated by IL-15 at doses of 25 ng/ml (16). It is
important to consider that optimal doses of IL-15 for proliferation
of NK cells and NKT-like cells are far lower than for CD8 T cells,
where a minimal 25 ng/ml is required for significant effects.
We wished to determine whether IL-15 upregulated
telomerase activity and expression in NK and NKT-like cells in
addition to CD8 T cells. Others have shown that the NK cell line,
NK-92 cells expresses TERT upon stimulation with IL-2 (40) and
that TERT transfection of NK cells can increase the longevity of
the cells to at least 1 year when stimulated with K562 feeder cells
expressing membrane-bound 4-1BB and IL-15 (41). In our
study, when comparing TERT expression in CD8, NK, and
NKT cells, we saw an upregulation of expression of the protein
in all three cell types in PBMCs from normal human donors.
This indicates that the replicative and lifespan potential impacted
by TERT activity in each of these three cell types are similarly
affected by IL-15. IL-15 upregulates TERT expression in NK, andFrontiers in Immunology | www.frontiersin.org 11NKT cells to a similar degree to that of CD8 T cells with a
maximal 2.5 fold increase in the intensity of expression in the
three cell types. The increases in TERT are concomitant with the
increased cell doubling as observed with changes in CFSE
intensity. IL-2 also upregulates TERT in the three cell types,
but only at doses of 100–1000 ng/ml and the increase is less
pronounced (a maximal 2-fold increase at 1000 ng/ml).
IL-15 upregulated HTERT in our experiments, to a maximum
of 300% (3-fold). Although the expression of HTERT mRNA has
been shown to increase by 8-fold in lymphocytes active by CD3/
CD28 (42), and others have reported increases in protein of a
similar magnitude using western blotting (40), westerns are
much more sensitive than flow cytometry so they are not a
direct comparison and an upregulation of mRNA may not
translate to the same increase in protein.
The TRAP assay also confirms that the activity of telomerase
is upregulated in both CD56+ and CD8 T cells to a similar degree
with IL-15. IL-15 could therefore be used as an alternative to
TERT transfection to increase the longevity of the three
cell types.
Telomere length is also a parameter that is used to analyze
telomerase activity. We considered carefully about including this
data in our study and assessed different methods for obtaining
the data for telomerase length. However, from our review of
the methods and the results obtained from telomerase length
analysis there is a large consensus that a) telomere length is a very
variable parameter and is influenced by many environmental
factors apart from the effects of cytokines, such as hormonal
factors, age, sex of the individual donor (43) and b) the length of
telomeres in individual leukocyte cells varies widely (44) so that
the mean telomerase length may not change with our agents and
the statistical power required to allow for the variance would
mean testing many more donors than is practically possible. A
previous study with lymphocytes examined telomere length with
no changes recorded either for activation with IL-2 or for
inhibition of activation with signaling inhibitors and this may
be due to the above factors (40).
When we investigated the phosphorylation of proteins of the
signaling pathways induced by IL-15 and IL-2, we found clear
differences in the activation induced by IL-15 and IL-2 among
the three cell types. In NK cells and NKT-like cells, IL-15
stimulated phosphorylation of a few selected proteins from the
three pathways: Creb. Stat5a/b, Tor, AMPKa1, AKT (T308), and
Hsp60. However, in CD8 T cells, there was increased
phosphorylation of a larger number of proteins from the array:
Creb, p38, ERK1/2, AKT (S473), AKT (T308), AMPKa1, p53
(s392), (s46), Tor, WNK1, Hsp60, Stat2, Stat5a, Stat5b, Stat5a/b,
Stat6. Treatment with the high dose of IL-2 also changed
phosphorylation of proteins in the three cell types, with
significant changes in, AMPK a1, Creb, Stat2, Stat5a, Stat5b,
Stat5a/b, and Stat6 in NKT-like and CD8 T cells and Creb,
AMPK a1, Stat5a/b, and Stat2 in NK cells. IL-15’s effects on the
proteins Creb, Stat5a/b, AKT, mTor, and Hsp60 were confirmed
from the western blots of the three cell types and the effects on
p38a, ERK and p53 were confirmed from western blots of the
CD8 T cells. However, for IL-2, the results of the array were notJanuary 2021 | Volume 11 | Article 594620
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase Expressionconfirmed for the western blots, with no change in Creb or
AMPK a1 in the three cell lines.
The signaling array results confirm that IL-15 impacts
signaling of a larger number of proteins in the three cell types
than IL-2, which may explain its stronger activity, compared to
IL-2 in the three cell types in cell expansion, TERT activity
and cell division. The strong induction of Creb, MTOR and
Hsp60 in all three cell types by IL-15 and not IL-2 may be a
significant finding in the possible greater activity of IL-15
compared to IL-2 in NK, NKT, and CD8 T cell proliferation.
The cAMP response element binding protein (CREB) is a well-
known phosphorylation-activated transcription factor and its
activation has been shown promote proliferation and survival
and differentially regulate Th1, Th2, and Th17 responses in T
and B cells (45). Furthermore it has been shown to inhibit the
proliferation of T regulatory cells, which may be a possible
contributor to the lack of Treg proliferation by IL-15 (46).
Mammalian target of rapamycin (mTOR) has been previously
shown to be important in the development and activation of NK
cells by IL-15 (47) and also increases the migration of resting
CD8 memory T cells to resident tissues (48). It is also known that
mTOR regulates telomerase activity at the translational and post-
translational level and that the inhibitor of mTOR, rapamycin,
can inhibit telomerase activity (49).
The heat shock protein Hsp60 is expressed in eukaryotic cells
as a response to a variety of stress stimuli, e.g. temperature
increase, nutrient deprivation, exposure to toxic chemicals,
inflammatory responses, and allograft rejection and it is known
to bind to HLA-E to attenuate inhibition of NK responses
through CD94/NKG2A recognition (50). The expression of
Hsp60 may therefore increase the activity of NK cells through
this mechanism. The heat shock proteins HSP90 and HSP70
have also been shown to be critical for NK cell function (51, 52)
and it is known that Hsp90 forms a complex with TERT to
increase the stability and activity of telomerase (53).
When we investigated the importance of the three signaling
pathways JAK/STAT, PI3/AKT and RAS/MAPK in the increase
in TERT expression mediated by IL-2 and IL-15, we showed that
whereas all three pathways are involved in the increase through
IL-2 in all three cell types, IL-15 mediated increases are
dependent on JAK1 and JAK3 and PI3K/AKT in NK cells and
NKT-like cells and all three pathways in CD8 T cells. The
patterns of HTERT inhibition closely match the patterns of the
inhibition of cell expansion and cell division. This finding is in
line with additional proteins impacted in the Ras/Mek/pathways
(ERk1/2 and p38a) in CD8 T cells by IL-15.
The dependence of TERT expression on all three signaling
pathways with IL-2 and with IL-15 in CD8 T cells, suggests that
any therapies that inhibit MEK/ERK pathways used in cancer
patients are likely to affect proliferation of CD8 T cells to a
greater extent than NK cells or NK-like cells.
Our study therefore demonstrates that IL-15 is preferable to
IL-2 as a proliferative tool for preparing NK, NKT, or CD8 T
cells for adoptive therapy and may be an alternative to the use of
TERT transfection for increasing the replicative potential of
these cells.Frontiers in Immunology | www.frontiersin.org 12DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/Supplementary Material. Further inquiries can be
directed to the corresponding author.AUTHOR CONTRIBUTIONS
CG obtained funding, created project and study, supervised staff
and students, and designed experiments. PD obtained funding,
recruited students to project, and developed concept. FW, SN, and
AR carried out experiments and analyzed and interpreted data. CS
and OE supervised FW and SN and interpreted and critiqued data.
EP read and critiqued manuscript and interpreted data. All authors
contributed to the article and approved the submitted version.FUNDING
The authors acknowledge financial support from Prostate
Cancer Research (charity grant 6938) and Prostate cancer UK
(grant PA-012).ACKNOWLEDGMENTS
The authors would like to acknowledge Dr. Ana Maria De Silva
Esteves for performing the lymphocyte viability experiment. The
authors would also like to thank Dr Susan John at the School of
Immunology and Microbial Sciences, Kings College London for
providing us with the Signalling pathway inhibitors for Jak1/3,
MEK/ERK, and PI3K/AKT, and advising us on their use.SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.
594620/full#supplementary-material
SUPPLEMENTARY FIGURE 1 | Gating strategy for live cells and viability of
lymphocytes with IL-15. To confirm that the gate we chose for lymphocytes for all
flow cytometry experiments corresponded to live cells, we set up non-adherent
lymphocytes for 7 days with either PBS or IL-15 at different concentrations. We then
stained different lymphocyte populations with CD3, CD56 and CD8 T cells and
included a live/dead stain APC-Cy7 stain (Thermofisher, UK). Panel (A) shows the
whole lymphocyte population on forward and side scatter without gating and the
corresponding channels showing the live/dead stain with fluorescence as APC-
Cy7-A on the near Infrared channel on the FACs canto. In Panel (B), when we gate
the lymphocytes using our gate selection, this corresponds to the gating of the live
cells with over 96% viable cells. Panel (C) shows that viability of the lymphocytes is
not affected with IL-15 or IL-2.
SUPPLEMENTARY FIGURE 2 | Dot plots showing the purity of (A) NKT, (B) NK
and (C) CD8 T cells isolated from the Miltenyi kits. Cells were isolated by Miltenyi kits
as described in the materials and methods and purity of the populations was
assessed by flow cytometry. Purity was recorded above 95% in line with the
standard kit isolation recommendations.January 2021 | Volume 11 | Article 594620
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase ExpressionREFERENCES
1. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy:
from T cell basic science to clinical practice. Nat Rev Immunol (2020) 20
(11):651–68. doi: 10.1038/s41577-020-0306-5
2. Payne KK, Bear HD, Manjili MH. Adoptive cellular therapy of cancer:
exploring innate and adaptive cellular crosstalk to improve anti-tumor
efficacy. Future Oncol (2014) 10(10):1779–94. doi: 10.2217/fon.14.97
3. Nayar S, Dasgupta P, Galustian C. Extending the lifespan and efficacies of
immune cells used in adoptive transfer for cancer immunotherapies-A review.
Oncoimmunology (2015) 4(4):11. doi: 10.1080/2162402x.2014.1002720
4. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell
carcinoma–predictors of response. Semin Oncol (2006) 33(5):583–7.
doi: 10.1053/j.seminoncol.2006.06.004
5. Conlon KC, Potter EL, Pittaluga S, Lee C-CR, Miljkovic MD, Fleisher TA, et al.
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a
Phase I Trial Induced Dramatic NK-Cell Subset Expansion. J Clin Cancer Res
(2019) 25(16):4945–54. doi: 10.1158/1078-0432.CCR-18-3468
6. Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA,
et al. A First-in-Human Phase I Study of Subcutaneous Outpatient
Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid
Tumors. Clin Cancer Res (2018) 24(7):1525–35. doi: 10.1158/1078-
0432.CCR-17-2451
7. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in
the life and death of lymphocytes: implications for immunotherapy.
Immunity (2001) 14(2):105–10. doi: 10.1016/S1074-7613(01)00093-0
8. Read KA, Powell MD, McDonald PW, Oestreich KJ. IL-2, IL-7, and IL-15:
Multistage regulators of CD4(+) T helper cell differentiation. Exp Hematol
(2016) 44(9):799–808. doi: 10.1016/j.exphem.2016.06.003
9. Waickman AT, Ligons DL, Hwang S, Park J-Y, Lazarevic V, Sato N, et al. CD4
effector T cell differentiation is controlled by IL-15 that is expressed and
presented in trans. Cytokine (2017) 99:266–74. doi: 10.1016/j.cyto.2017.
08.004
10. Berard M, Brandt K, Paus SB, Tough DF. IL-15 Promotes the Survival of
Naive and Memory Phenotype CD8&lt;sup<+&lt;/sup< T Cells. J Immunol
(2003) 170(10):5018. doi: 10.4049/jimmunol.170.10.5018
11. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al.
Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells
via components of the IL-2 receptor. J Exp Med (1994) 180(4):1395–403. doi:
10.1084/jem.180.4.1395
12. Lu J, Giuntoli RL, Omiya R, Kobayashi H. R. Kennedy and E. Celis:
Interleukin 15 promotes antigen-independent in vitro expansion and long-
term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res (2002) 8
(12):3877–84.
13. Gordy LE, Bezbradica JS, Flyak AII, Spencer CT, Dunkle A, Sun J, et al. IL-15
regulates homeostasis and terminal maturation of NKT cells. J Immunol
(2011) 187(12):6335–45. doi: 10.4049/jimmunol.1003965
14. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic
implications in cancer. Trends Pharmacol Sci (2012) 33(1):35–41.
doi: 10.1016/j.tips.2011.09.004
15. Lieberman LA, Villegas EN, Hunter CA. Interleukin-15-Deficient Mice
Develop Protective Immunity to &lt;em<Toxoplasma gondii&lt;/em&gt.
Infect Immun (2004) 72(11):6729. doi: 10.1128/IAI.72.11.6729-6732.2004
16. Sakellariou C, Elhage O, Papaevangelou E, Giustarini G, Esteves AM,
Smolarek D, et al. Prostate cancer cells enhance interleukin-15-mediated
expansion of NK cells. BJU Int (2020) 125(1):89–102. doi: 10.1111/bju.14893
17. Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15
signaling in health and in cancer. Clin Cancer Res (2014) 20(8):2044–50.
doi: 10.1158/1078-0432.CCR-12-3603
18. Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol
(2013) 8:49–78. doi: 10.1146/annurev-pathol-020712-164030
19. Hodes RJ, Hathcock KS, Weng NP. Telomeres in T and B cells. Nat Rev
Immunol (2002) 2(9):699–706. doi: 10.1038/nri890
20. Hahn WC. Role of Telomeres and Telomerase in the Pathogenesis of Human
Cancer. J Clin Oncol (2003) 21(10):2034–43. doi: 10.1200/JCO.2003.06.018
21. Li Y, Zhi W, Wareski P, Weng NP. IL-15 activates telomerase and minimizes
telomere loss and may preserve the replicative life span of memory CD8+ TFrontiers in Immunology | www.frontiersin.org 13cells in vitro. J Immunol (2005) 174(7):4019–24. doi: 10.4049/
jimmunol.174.7.4019
22. Yamada O, Kawauchi K. The role of the JAK-STAT pathway and related
signal cascades in telomerase activation during the development of
hematologic malignancies. JAK-STAT (2013) 2(4):e25256–6. doi: 10.4161/
jkst.25256
23. Jiang Y, Cui X, Cui C, Zhang J, Zhou F, Zhang Z, et al. The Function of
CD3+CD56+ NKT-Like Cells in HIV-Infected Individuals. BioMed Res Int
(2014) 2014:863625. doi: 10.1155/2014/863625
24. Li Z,WuY,Wang C, ZhangM.Mouse CD8+NKT-like cells exert dual cytotoxicity
against mouse tumor cells and myeloid-derived suppressor cells. Cancer Immunol
Immunother (2019) 68(8):1303–15. doi: 10.1007/s00262-019-02363-3
25. Wang Y, Zheng X, Wei H, Sun R, Tian Z. Different roles of IL-15 from IL-2 in
differentiation and activation of human CD3+CD56+ NKT-like cells from
cord blood in long term culture. Int Immunopharmacol (2008) 8(6):927–34.
doi: 10.1016/j.intimp.2008.02.011
26. Wang H, Yang D, Xu W, Wang Y, Ruan Z, Zhao T, et al. Tumor-derived
soluble MICs impair CD3+CD56+ NKT-like cell cytotoxicity in cancer
patients. Immunol Lett (2008) 120(1):65–71. doi: 10.1016/j.imlet.2008.07.001
27. Wang C, Liu X, Li Z, Chai Y, Jiang Y, Wang Q, et al. CD8(+)NKT-like cells
regulate the immune response by killing antigen-bearing DCs. Sci Rep (2015)
5:14124–4. doi: 10.1038/srep14124
28. Nguyen HH, Kim T, Song SY, Park S, Cho HH, Jung S-H, et al. Naïve CD8+ T
cell derived tumor-specific cytotoxic effectors as a potential remedy for
overcoming TGF-b immunosuppression in the tumor microenvironment.
Sci Rep (2016) 6(1):28208. doi: 10.1038/srep28208
29. Grievink HW, Luisman T, Kluft C, Moerland M, Malone KE. Comparison of
Three Isolation Techniques for Human Peripheral Blood Mononuclear Cells:
Cell Recovery and Viability, Population Composition, and Cell Functionality.
Biopreserv Biobanking (2016) 14(5):410–5. doi: 10.1089/bio.2015.0104
30. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH,
et al. Prevention of organ allograft rejection by a specific Janus kinase 3
inhibitor. Science (2003) 302(5646):875–8. doi: 10.1126/science.1087061
31. Jiang H, Fan D, Zhou G, Li X, Deng H. Phosphatidylinositol 3-kinase inhibitor
(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro
and in vivo. J Exp Clin Cancer Res CR (2010) 29(1):34–4. doi: 10.1186/1756-
9966-29-34
32. Marzec M, Liu X, Kasprzycka M, Witkiewicz A, Raghunath PN, El-Salem M,
et al. IL-2– and IL-15–induced activation of the rapamycin-sensitive
mTORC1 pathway in malignant CD4+ T lymphocytes. Blood (2008) 111
(4):2181–9. doi: 10.1182/blood-2007-06-095182
33. Huang P, Watanabe M, Kaku H, Kashiwakura Y, Chen J, Saika T, et al. Direct
and distant antitumor effects of a telomerase-selective oncolytic adenoviral
agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ther (2008)
15(5):315–22. doi: 10.1038/cgt.2008.3
34. Peng L-S, Mao F-Y, Zhao Y-L, Wang T-T, Chen N, Zhang J-Y, et al. Altered
phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in
human gastric cancer. Oncotarget (2016) 7(34):55222–30. doi: 10.18632/
oncotarget.10484
35. Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P,
et al. Highly effective NK cells are associated with good prognosis in patients
with metastatic prostate cancer. Oncotarget (2015) 6(16):14360–73.
doi: 10.18632/oncotarget.3965
36. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio
are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci
(2005) 102(51):18538–43. doi: 10.1073/pnas.0509182102
37. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C,
et al. Type, density, and location of immune cells within human colorectal
tumors predict clinical outcome. Science (2006) 313(5795):1960–4.
doi: 10.1126/science.1129139
38. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH,
et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast
cancer. J Clin Oncol (2011) 29(15):1949–55. doi: 10.1200/jco.2010.30.5037
39. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM,
et al. Massive ex Vivo Expansion of Human Natural Regulatory T Cells with
Minimal Loss of in Vivo Functional Activity. Sci Trans Med (2011) 3
(83):83ra41. doi: 10.1126/scitranslmed.3001809January 2021 | Volume 11 | Article 594620
Watkinson et al. IL-15 Increases NK/NKT/CD8 Telomerase Expression40. Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse
transcriptase activity transcriptionally and posttranslationally through
phosphatidylinositol 3’-kinase/Akt, heat shock protein 90, and mammalian
target of rapamycin in transformed NK cells. J Immunol (2005) 174(9):5261–
9. doi: 10.4049/jimmunol.174.9.5261
41. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative
potential of human natural killer cells. Br J Haematol (2009) 145(5):606–13.
doi: 10.1111/j.1365-2141.2009.07667.x
42. Liu K, SchoonmakerMM, Levine BL, June CH, Hodes RJ,Weng N-P. Constitutive
and regulated expression of telomerase reverse transcriptase (hTERT) in human
lymphocytes. Proc Natl Acad Sci (1999) 96(9):5147. doi: 10.1073/pnas.96.9.5147
43. Lulkiewicz M, Bajsert J, Kopczynski P, Barczak W, Rubis B. Telomere length:
how the length makes a difference. Mol Biol Rep (2020) 47(9):7181–8.
doi: 10.1007/s11033-020-05551-y
44. Factor-Litvak P, Susser E, Kezios K, McKeague I, Kark JD, Hoffman M, et al.
Leukocyte Telomere Length in Newborns: Implications for the Role of Telomeres in
Human Disease. Pediatrics (2016) 137(4):e20153927. doi: 10.1542/peds.2015-3927
45. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB
in immune function. J Immunol (Baltimore Md 1950) (2010) 185(11):6413–9.
doi: 10.4049/jimmunol.1001829
46. Wang X, Ni L, Chang D, Lu H, Jiang Y, Kim B-S, et al. Cyclic AMP-
Responsive Element-Binding Protein (CREB) is Critical in Autoimmunity by
Promoting Th17 but Inhibiting Treg Cell Differentiation. EBioMedicine
(2017) 25:165–74. doi: 10.1016/j.ebiom.2017.10.010
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